Interrogating open issues in cancer precision medicine with patient-derived xenografts

Area of Science:

• Oncology
• Translational Cancer Research
• Biomedical Science

Background:

• Patient-derived xenografts (PDXs) are valuable preclinical models in oncology.
• PDXs enable the study of tumor heterogeneity, cancer evolution, and treatment resistance.
• Current research focuses on improving PDX model predictability for clinical outcomes.

Purpose of the Study:

• To discuss the utility of PDX models in addressing key questions in oncology.
• To highlight advancements in PDX modeling, including humanization and co-clinical trials.
• To emphasize the benefits of shared PDX resources for cancer research.

Main Methods:

• Review of current literature and practices in PDX modeling.
• Discussion of strategies to enhance PDX model relevance (e.g., mouse humanization).
• Exploration of co-clinical trial frameworks utilizing PDXs.

Main Results:

• PDX models are instrumental in investigating therapeutic responsiveness and resistance mechanisms.
• Tumor heterogeneity and evolutionary dynamics can be effectively studied using PDXs.
• Co-clinical trials and shared resources enhance the clinical translation of PDX findings.

Conclusions:

• PDX models are critical for understanding cancer biology and developing novel treatments.
• Advancements in PDX technology are improving their predictive capacity for clinical success.
• Collaborative efforts, such as EurOPDX, are vital for maximizing the impact of PDX research in cancer medicine.